Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
Date:5/16/2013

SAN FRANCISCO, May 16, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming 2013 UBS Global Healthcare Conference in New York at the Sheraton New York Hotel on Tuesday, May 21, 2013 at 10:00 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted in the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until June 22, 2013.

About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 development as a once- daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.  Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contact:
Jennifer Ruddock /Nektar Therapeutics
(415) 482-5585


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2019)... LOUISVILLE, Ky. (PRWEB) , ... June 13, 2019 , ... ... 12 months for a long-term client in the healthcare space. The $5.8M in savings ... total realized bottom line improvement to $23.4M. , With an acquisition in Q4 2019, ...
(Date:6/13/2019)... , ... June 13, 2019 , ... Access Healthcare ... it will be attending and exhibiting at the HFMA Annual Conference 2019 ... Tassoni , President (US Operations) of Access Healthcare, says, “HFMA Annual Conference has inspired ...
(Date:6/13/2019)... Pa. (PRWEB) , ... June 13, 2019 , ... HMP, ... has been recognized as one of the “Top 25 Fastest-Growing Shows in Net Square ... 2016-2018 and is ranked by overall attendance growth over that period. Winners will be ...
Breaking Medicine Technology:
(Date:6/18/2019)... ... June 18, 2019 , ... NeoTract, a ... the field of urology, today announced that Aaron Berger, MD, Associated Urological Specialists, ... The designation recognizes that Dr. Aaron Berger has achieved a high level of ...
(Date:6/16/2019)... SPRINGFIELD, Mo. (PRWEB) , ... June 15, 2019 , ... ... Convoy of Hope has been committed to helping those in need around the world. ... people in more than 125 countries. Convoy’s work would not be possible without the ...
(Date:6/14/2019)... ... ... This past Saturday, volunteers from Bright Now! Dental delivered smiles ... Day of Giving, where members of underserved communities were able to receive pro bono ... the Smiles for Everyone Foundation. Some of these organizations include Stella ...
(Date:6/13/2019)... (PRWEB) , ... June 13, 2019 , ... ... ROSA® Beta-lactam 30 Second Test (BL30SEC) has been accepted by the 2019 National ... Milk Ordinance Appendix N requirements. , The Charm BL30SEC test was validated ...
(Date:6/13/2019)... ... June 13, 2019 , ... The Stevie® ... the second annual Women|Future Conference and the advisory board that is ... position themselves and their organizations in tomorrow's marketplace. , The mission of the ...
Breaking Medicine News(10 mins):